In which patients with stage IV NSCLC and PD-L1 TPS >50% plus concomitant autoimmune disease is it considered safe to give immune checkpoint blockers?   

Given the adverse events of special interest noted with immune checkpoint blockers - specifically immune related AEs (or irAEs), the safety (and efficacy) of using these drugs in patients with pre-existing autoimmune disorders is not entirely clear. To date, most (if not all) studies have excluded p...